Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Meloxicam 15 milligram

Phase 2Small molecule

IInnovaGyn, Inc.

Meloxicam 15 milligram is one of 2 small molecule programs targeting Pregnancy Prevention. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pregnancy PreventionCompleted

Pregnancy PreventionPhase 2

Completed

Competition

Competitive Landscape

1 competitor in Pregnancy Prevention

#DrugCompanyPhaseTrials

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Meloxicam 15 milligram

IInnovaGyn, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pregnancy Prevention1 trial

A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women

Completed·IInnovaGyn, Inc.·Phase 2·NCT06306131·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Meloxicam 15 milligram. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meloxicam 15 milligram compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meloxicam 15 milligram. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InnovaGyn, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInnovaGyn, Inc.

Related News